Skip to main content
Top
Published in: Pituitary 2/2014

01-04-2014

Absence of immunostaining for growth hormone in a subset of patients with acromegaly

Authors: Jason L. Schroeder, Alejandro M. Spiotta, Maria Fleseriu, Richard A. Prayson, Amir H. Hamrahian, Robert J. Weil

Published in: Pituitary | Issue 2/2014

Login to get access

Abstract

The presence of growth hormone (GH) immunostaining in patients who lack the biochemical and clinical features of acromegaly has been described. In contrast, there is little information on the absence of GH immunostaining in patients with acromegaly. We describe five patients with acromegaly with no intratumoral immunostaining for GH. We reviewed all patients undergoing surgery for acromegaly. Out of 136 patients treated surgically in a 10 year period, five (3.7 %) were found to have no GH immunostaining on repetitive testing at pathological examination. Their pathology slides were re-examined by an experienced neuropathologist, along with twenty nonfunctional pituitary tumors and ten GH-positive adenomas as negative and positive controls, respectively. All patients had clinical features consistent with acromegaly and elevated baseline insulin-like growth factor-1 (IGF-1) and GH. All patients had no immunostaining for GH on multiple inspections. Of twenty patients with nonfunctional tumors, two had ≤25 % staining for GH in a scattered and non-coherent pattern and the rest were negative. In all ten positive control patients >25 % of the tumor cells stained diffusely for GH. All five patients achieved biochemical remission at 1.4–8 years post-op using a combination of primary surgery alone (n = 1), repeat surgery (n = 1), radiotherapy (n = 3) and/or medical therapy (n = 2). GH immunostaining of an adenoma may not be sufficient to confirm the diagnosis of acromegaly. All patients in our small series achieved remission by multimodality therapies. Further studies are needed to evaluate the significance of our observation and whether this subset of patients follows a distinct long term clinical course.
Literature
2.
go back to reference Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223(4):327–335PubMedCrossRef Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223(4):327–335PubMedCrossRef
3.
go back to reference Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41(1):95–102CrossRef Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41(1):95–102CrossRef
4.
go back to reference Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83(8):2730–2734PubMed Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 83(8):2730–2734PubMed
6.
go back to reference Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90(7):4081–4086. doi:10.1210/jc.2004-1381 PubMedCrossRef Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90(7):4081–4086. doi:10.​1210/​jc.​2004-1381 PubMedCrossRef
7.
go back to reference Sidhaye A, Burger P, Rigamonti D, Salvatori R (2005) Giant somatotrophinoma without acromegalic features: more “quiet” than “silent”: case report. Neurosurgery 56(5), E1154; discussion E1154 Sidhaye A, Burger P, Rigamonti D, Salvatori R (2005) Giant somatotrophinoma without acromegalic features: more “quiet” than “silent”: case report. Neurosurgery 56(5), E1154; discussion E1154
9.
go back to reference Kovacs K, Lloyd R, Horvath E, Asa SL, Stefaneanu L, Killinger DW, Smyth HS (1989) Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. Am J Pathol 134(2):345–353PubMedCentralPubMed Kovacs K, Lloyd R, Horvath E, Asa SL, Stefaneanu L, Killinger DW, Smyth HS (1989) Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. Am J Pathol 134(2):345–353PubMedCentralPubMed
12.
go back to reference Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W (1980) Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98(3):617–638PubMedCentralPubMed Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W (1980) Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98(3):617–638PubMedCentralPubMed
13.
go back to reference Yamada S, Sano T, Stefaneanu L, Kovacs K, Aiba T, Sawano S, Shishiba Y (1993) Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. J Clin Endocrinol Metab 76(2):352–356PubMed Yamada S, Sano T, Stefaneanu L, Kovacs K, Aiba T, Sawano S, Shishiba Y (1993) Endocrine and morphological study of a clinically silent somatotroph adenoma of the human pituitary. J Clin Endocrinol Metab 76(2):352–356PubMed
14.
go back to reference Trouillas J, Sassolas G, Loras B, Velkeniers B, Raccurt M, Chotard L, Berthezene F, Tourniaire J, Girod C (1991) Somatotropic adenomas without acromegaly. Pathol Res Pract 187(8):943–949PubMedCrossRef Trouillas J, Sassolas G, Loras B, Velkeniers B, Raccurt M, Chotard L, Berthezene F, Tourniaire J, Girod C (1991) Somatotropic adenomas without acromegaly. Pathol Res Pract 187(8):943–949PubMedCrossRef
15.
go back to reference Lloyd RV, Cano M, Chandler WF, Barkan AL, Horvath E, Kovacs K (1989) Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization. Am J Pathol 134(3):605–613PubMedCentralPubMed Lloyd RV, Cano M, Chandler WF, Barkan AL, Horvath E, Kovacs K (1989) Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization. Am J Pathol 134(3):605–613PubMedCentralPubMed
16.
go back to reference Lonser RR, Ksendzovsky A, Wind JJ, Vortmeyer AO, Oldfield EH (2012) Prospective evaluation of the characteristics and incidence of adenoma-associated dural invasion in Cushing disease. J Neurosurg 116(2):272–279. doi:10.3171/2011.8.JNS11456 PubMedCrossRef Lonser RR, Ksendzovsky A, Wind JJ, Vortmeyer AO, Oldfield EH (2012) Prospective evaluation of the characteristics and incidence of adenoma-associated dural invasion in Cushing disease. J Neurosurg 116(2):272–279. doi:10.​3171/​2011.​8.​JNS11456 PubMedCrossRef
19.
go back to reference Hofland LJ, van Koetsveld PM, Verleun TM, Lamberts SW (1989) Glycoprotein hormone alpha-subunit and prolactin release by cultured pituitary adenoma cells from acromegalic patients: correlation with GH release. Clin Endocrinol (Oxf) 30(6):601–611CrossRef Hofland LJ, van Koetsveld PM, Verleun TM, Lamberts SW (1989) Glycoprotein hormone alpha-subunit and prolactin release by cultured pituitary adenoma cells from acromegalic patients: correlation with GH release. Clin Endocrinol (Oxf) 30(6):601–611CrossRef
20.
go back to reference Trouillas J, Girod C, Lheritier M, Claustrat B, Dubois MP (1980) Morphological and biochemical relationships in 31 human pituitary adenomas with acromegaly. Virchows Arch A Pathol Anat Histol 389(2):127–142PubMedCrossRef Trouillas J, Girod C, Lheritier M, Claustrat B, Dubois MP (1980) Morphological and biochemical relationships in 31 human pituitary adenomas with acromegaly. Virchows Arch A Pathol Anat Histol 389(2):127–142PubMedCrossRef
21.
go back to reference Klijn JG, Lamberts SW, de Jong FH, van Dongen KJ, Birkenhager JC (1980) Interrelationships between tumour size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinol (Copenh) 95(3):289–297 Klijn JG, Lamberts SW, de Jong FH, van Dongen KJ, Birkenhager JC (1980) Interrelationships between tumour size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinol (Copenh) 95(3):289–297
22.
go back to reference Herzog T, Schlote W, Lorenz R, Jungmann E, Althoff PH (1993) Pituitary adenomas: serum hormone levels and immunohistochemical staining for ACTH GH and prolactin. Clin Neuropathol 12(2):117–120PubMed Herzog T, Schlote W, Lorenz R, Jungmann E, Althoff PH (1993) Pituitary adenomas: serum hormone levels and immunohistochemical staining for ACTH GH and prolactin. Clin Neuropathol 12(2):117–120PubMed
23.
go back to reference Ho DM, Hsu CY, Ting LT, Chiang H (2001) Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification. Histopathology 39(3):310–319PubMedCrossRef Ho DM, Hsu CY, Ting LT, Chiang H (2001) Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification. Histopathology 39(3):310–319PubMedCrossRef
24.
go back to reference Oka H, Kameya T, Sato Y, Naritaka H, Kawano N (1999) Significance of growth hormone-releasing hormone receptor mRNA in non-neoplastic pituitary and pituitary adenomas: a study by RT-PCR and in situ hybridization. J Neurooncol 41(3):197–204PubMedCrossRef Oka H, Kameya T, Sato Y, Naritaka H, Kawano N (1999) Significance of growth hormone-releasing hormone receptor mRNA in non-neoplastic pituitary and pituitary adenomas: a study by RT-PCR and in situ hybridization. J Neurooncol 41(3):197–204PubMedCrossRef
25.
go back to reference Saeger W, Uhlig H, Baz E, Fehr S, Ludecke DK (1991) In situ hybridization for different mRNA in GH-secreting and in inactive pituitary adenomas. Pathol Res Pract 187(5):559–563PubMedCrossRef Saeger W, Uhlig H, Baz E, Fehr S, Ludecke DK (1991) In situ hybridization for different mRNA in GH-secreting and in inactive pituitary adenomas. Pathol Res Pract 187(5):559–563PubMedCrossRef
Metadata
Title
Absence of immunostaining for growth hormone in a subset of patients with acromegaly
Authors
Jason L. Schroeder
Alejandro M. Spiotta
Maria Fleseriu
Richard A. Prayson
Amir H. Hamrahian
Robert J. Weil
Publication date
01-04-2014
Publisher
Springer US
Published in
Pituitary / Issue 2/2014
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0474-4

Other articles of this Issue 2/2014

Pituitary 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.